1 |
Chan A, Chen C, Chiang J, et al (2012). Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer, 1525-32.
|
2 |
Chayakulkeeree M, Thamlikitkul V (2003). Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever. J Med Assoc Thai, 86, 212-23.
|
3 |
Chindaprasirt J, Wanitpongpun C, Limpawattana P, et al (2013). Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. Asian Pac J Cancer Prev, 14, 1115-9.
DOI
ScienceOn
|
4 |
Choi YW, Jeong SH, Ahn MS, et al (2014). Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab- CHOP. J Korean Med Sci, 1493-500.
|
5 |
Crawford J, Armitage J, Balducci L, et al (2013). Myeloid growth factors. J Natl Compr Canc Netw, 11, 1266-90.
|
6 |
Crawford J, Dale DC, Kuderer NM, et al (2008). Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw, 6, 109-18.
|
7 |
Freifeld AG, Bow EJ, Sepkowitz KA, et al (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis, 52, 56-93.
DOI
ScienceOn
|
8 |
Hassan BAR, Yusoff ZBM, Ohtman SB (2009). Neutropenia onset, severity, and their association with demographic data. Asian J Pharm Clin Res, 2, 51-3.
|
9 |
Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al (2000). A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma, 37, 351-60.
|
10 |
Klastersky J (2004). Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis, 39, 32-7.
DOI
|
11 |
Klastersky J, Paesmans M, Rubenstein EB, et al (2000). The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol, 18, 3038-51.
|
12 |
Kuderer NM, Dale DC, Crawford J, et al (2007). Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol, 25, 3158-67.
DOI
|
13 |
Lal A, Bhurgri Y, Rizvi N, et al (2008). Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia. Asian Pac J Cancer Prev, 9, 303-8.
|
14 |
Leelayuthachai T, Kanitsap N (2010). Febrile neutropenia in post-chemotherapeutic patients in medicine department, thammasat university hospital. J Hematol Transfus Med, 20, 197-203.
|
15 |
Lyman GH, Kuderer NM, Crawford J, et al (2011). Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer, 117, 1917-27.
DOI
|
16 |
Lyman GH, Michels SL, Reynolds MW, et al (2010). Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer, 116, 5555-63.
DOI
|
17 |
Salar A, Haioun C, Rossi FG, et al (2012). The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res, 36, 548-53.
DOI
|
18 |
Osmani AH, Ansari TZ, Masood N, et al (2012). Outcome of febrile neutropenic patients on granulocyte colony stimulating factor in a tertiary care hospital. Asian Pac J Cancer Prev, 13, 2523-6.
DOI
ScienceOn
|
19 |
Pettengell R, Bosly A, Szucs TD, et al (2009). Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol, 144, 677-85.
DOI
|
20 |
Roongpoovapatr P, Suankratay C (2010). Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital. J Med Assoc Thai, 93, 776-83.
|
21 |
Wolff D, Culakova E, Poniewierski MS, et al (2005). Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol, 3, 24-5.
|